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Buruli ulcer (BU), caused by Mycobacterium ulcer-
ans (Mu), is the third most common mycobacte-
rial disease, after tuberculosis and leprosy, and 
represents an emerging global threat, with a 
markedly increased incidence in tropical coun-
tries over the last decade (1). Infection with Mu 
leads to destruction of both cutaneous and subcu-
taneous tissues. The pathology of BU is strongly 
associated with the production of mycolactone, 
because injection of purifi  ed toxin into the skin 
of guinea pigs is suffi   cient to provoke ulcers, and 
strains of Mu defi  cient for its biosynthesis do not 
cause disease (2).
The human immune response to Mu follows 
a complex scheme consisting of three phases. 
Lesions typically start as a single, painless, acid-fast 
positive subcutaneous nodule, edema, or plaque, 
enlarging over time. Histopathological analysis 
of human and animal skin biopsies (3–5), as well 
as quantitative measurement of cytokine mRNAs 
in human tissues (6, 7), have shown that nod-
ules are the site of potent Th1 cell–oriented anti-
mycobacterial infl  ammatory responses. As the 
disease progresses, ulcers eventually form and 
are characterized by extensive necrosis of subcuta-
neous tissues and dermal collagen (4). Surprisingly, 
in the face of considerable cellular necrosis, 
there is minimal infl  ammation. Moreover, sup-
pression of Th 1 responses, as indicated by de-
fective systemic production of IFN-γ, has been 
repeatedly reported in BU patients with active 
ulcers (7–12). Importantly, the defect in the 
IFN-γ response by T cells is not antigen specifi  c 
and resolves during healing or after surgical 
excision of the lesions (11, 12), thus indicating 
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Mycolactone is a polyketide toxin produced by Mycobacterium ulcerans (Mu), the causative 
agent of the skin disease Buruli ulcer (BU). Surprisingly, infected tissues lack infl  ammatory 
infi  ltrates. Structural similarities between mycolactone and immunosuppressive agents led 
us to investigate the immunomodulatory properties of mycolactone on dendritic cells (DCs), 
the key initiators and regulators of immune responses. At noncytotoxic concentrations, 
phenotypic and functional maturation of both mouse and human DCs was inhibited by 
mycolactone. Notably, mycolactone blocked the emigration of mouse-skin DCs to draining 
lymph nodes, as well as their maturation in vivo. In human peripheral blood–derived DCs, 
mycolactone inhibited the ability to activate allogeneic T cell priming and to produce 
infl  ammatory molecules. Interestingly, production of the cytokines interleukin (IL) 12, tumor 
necrosis factor 𝗂, and IL-6 was only marginally affected, whereas production of the chemo-
kines macrophage infl  ammatory protein (MIP) 1𝗂, MIP-1𝗃, regulated on activation, normal 
T cell expressed and secreted, interferon 𝗄–inducible protein 10, and monocyte chemo-
attractant protein 1 was abolished at nanomolar concentrations. Importantly, mycolactone 
endogenously expressed by Mu mediated similar inhibitory effects on 𝗃-chemokine produc-
tion by DCs. In accordance with the histopathological features of BUs, our results suggest 
that bacterial production of mycolactone may limit both the initiation of primary immune 
responses and the recruitment of infl  ammatory cells to the infection site. Moreover, they 
highlight a potential interest in mycolactone as a novel immunosuppressive agent.
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that the presence of Mu is critical for local and systemic sup-
pression of cellular responses.
Intriguingly, the structure of mycolactone reveals a mac-
rocyclic polyketide, typical of a large class of natural products 
produced by actinomycetes. The structure of mycolactone 
shares similar features with the macrocyclic triene rapamycin 
from Streptomyces, the macrolide lactone FK506, and the soil 
fungi metabolite cyclosporine A, all potent immunosuppres-
sive drugs altering the functional immunobiology of lym-
phocytes and DCs (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20070234/DC1). DCs are key 
players in the initiation of cellular responses and the regulatory 
processes leading to impaired cellular immunity. On the basis 
of the structural resemblances of mycolactone with these 
  immunosuppressors, and from the observation that BU patients 
with active ulcers display cellular anergy, we postulated that 
mycolactone may exert immunomodulatory properties on DCs. 
The present study utilizes both mouse and human primary 
DCs and demonstrates that mycolactone is indeed a potent 
suppressor of the capacity of DCs to prime cellular immune 
responses and produce the chemotactic signals critical for the 
initiation of an infl  ammatory response. Our results provide 
novel information into the pathogenesis of Mu infection and 
further characterize a potentially useful immunosuppres-
sive agent.
RESULTS
Effect of mycolactone on DC viability
Given the data that mycolactone induces cell death in several 
cell types, it was initially important to assess the impact of the 
toxin on DC viability. The induction of apoptosis in immature 
and mature DC (iDC and mDC, respectively) preparations 
after exposure to mycolactone for 24–48 h was determined 
by phosphatidylserine exposure (Annexin V staining) and loss of 
membrane integrity (propidium iodide [PI] staining). In both 
mouse and human DCs, we observed a dose-dependent in-
crease in the percentage of apoptotic iDCs (Fig. 1, A and C). 
Induction of apoptosis nevertheless remained marginal with 
mycolactone doses <50 ng/ml. Interestingly, iDCs of both 
mouse and human origin were more sensitive to mycolactone-
induced apoptosis than mDCs (Fig. 1, B and D). This was the 
case when LPS or TNF was used as a maturation stimulus. Of 
note, only low levels of necrotic cells were observed in the 
cell cultures (unpublished data).
Mycolactone inhibits DC maturation
We next examined whether the maturation of DCs is infl  u-
enced by exposure to mycolactone. Only mycolactone doses 
<50 ng/ml were considered, and PI+ cells were excluded 
Figure 1.  DCs survive exposure to mycolactone doses <50 ng/ml. 
(A and B) Induction of apoptosis in mouse bone marrow–derived DCs 
after exposure to mycolactone. The analysis was performed on CD11c+-
gated cells incubated with mycolactone for 24 or 48 h concomitantly with 
10 ng/ml LPS (iDCs) or after 24 h of stimulation with 10 ng/ml LPS (mDCs). 
(C and D) Induction of apoptosis in human peripheral blood–derived 
DCs incubated with mycolactone for 24 or 48 h concomitantly (iDCs) 
or after 48 h of stimulation with TNF-α/PGE2 (mDCs). Annexin V+/PI− 
cells were identifi  ed as early apoptotic cells, Annexin V+/PI+ cells were 
identifi  ed as late apoptotic cells, and Annexin V−/PI− cells were identifi  ed 
as live cells. Data are mean percentages and are representative of three 
independent experiments.
Figure 2.  Mycolactone blocks DC maturation. (A) Representative 
histograms of CD83 and CD25 expression on human iDCs after stimula-
tion by TNF-α/PGE2 in the presence of increasing doses of mycolactone 
for 48 h. (B) MFI of CD83 and CD25 expression on iDCs after stimulation 
by TNF-α/PGE2 for 48 h in the presence of mycolactone. Each line corre-
sponds to one of the n donors.JEM VOL. 204, June 11, 2007  1397
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from the fl  ow cytometric analysis. A strong inhibitory eff  ect 
was seen in human iDCs matured by TNF-α/prostaglandin 
E2 (PGE2), as demonstrated by the failure to up-regulate 
CD83 and CD25 (Fig. 2 A). Although the mean fl  uorescence 
intensity (MFI) for CD83 and CD25 expression varied among 
donors, we observed a reproducible inhibition of maturation 
when iDCs were exposed to mycolactone (Fig. 2 B). To bet-
ter quantify the inhibitory eff  ect of mycolactone, the per-
centage of inhibition was calculated for several DC maturation 
markers (CD83, CD25, CD80, and CD40; Table I). Data 
from iDCs exposed to maturation stimuli for 24 and 48 h are 
shown. CD83 was the most aff  ected marker, with a signifi  -
cant reduction in surface expression 24 h after treatment in 
the presence of 20 ng/ml mycolactone. CD25 expression was 
also markedly altered, whereas the expression of CD80 and 
CD40 was only marginally modifi  ed. Similarly, in mouse 
iDCs stimulated with LPS in the presence of mycolactone, 
we observed a dose-dependent inhibition of CD86 and 
MHC class II surface expression (unpublished data). To 
determine if this eff  ect was reversible, we washed out the 
mycolactone after 24 h and returned them to culture wells 
containing maturation stimuli. In both the mouse and hu-
man culture systems, inhibition of maturation persisted af-
ter mycolactone was removed from the culture medium 
(unpublished data).
Mycolactone inhibits functional maturation and migration 
programs in DCs
To evaluate mycolactone eff  ects on DC migration, we used 
an in vivo migration model in which TNF-α is injected in-
tradermally into the ear, which triggers a massive traffi   cking 
of DCs into the auricular draining lymph node (ADLN) (13). 
DC migration was quantifi  ed by sacrifi  cing the mice after 4 h 
and assessing the number and maturation state of DCs emi-
grating from the skin. When mycolactone was coadminis-
tered with TNF-α, we observed a striking reduction in the 
proportion of migratory DCs (Fig. 3 A). In addition, we ob-
served a reduced CD86 and MHC class II surface expression 
on DCs that crawled out of the skin, as well as on DCs that 
reached ADLNs in the conditions under which mice had 
been injected with mycolactone (Fig. 3 B and not depicted). 
These data indicated that mycolactone impairs the capac-
ity of DCs to undergo maturation and up-regulate the ma-
chinery required for eff  ective migration to the draining 
lymph node.
We also observed an inhibition of functional maturation in 
human DCs. This was shown by assaying for the priming of 
allogeneic T cells in a mixed lymphocyte reaction. Strikingly, 
exposure of DCs to 10 ng/ml mycolactone during matura-
tion resulted in >70% inhibition of their allostimulatory ca-
pacity (Fig. 4). Collectively, the data in Figs. 2–4 demonstrate 
that exposure of DC to noncytotoxic doses of mycolactone 
results in the inhibition of both phenotypic and functional 
maturation of DCs.
Figure 3.  Mycolactone inhibits functional maturation of DCs 
in vivo. (A) Mice were injected intradermally into the ear with TNF-α alone 
(−) or TNF-α + mycolactone (+). After 4 h, mice were killed. Ear explants 
were placed in an overnight culture, and the number of DCs in the crawl-
out population was determined. Data are means and SD of CD11c+ PI− 
cell numbers from pooled skin explant cultures of two independent 
  experiments. (B) Histograms of MHC class II and CD86 expression on DCs 
(CD11c+ PI−) from skin explant cultures of mice injected with TNF-α 
alone (white) or TNF-α + mycolactone (black). Data are representative of 
pooled skin explant cultures from two independent experiments.
Figure 4.  Mycolactone reduces the allostimulatory capacity of 
human DCs. The proliferation of peripheral blood lymphocytes after 
incubation with allogeneic mycolactone-treated DCs is shown. DCs were 
matured in vitro with TNF-α/PGE2 in the presence of 0, 10, or 25 ng/ml 
mycolactone for 48 h and extensively washed before addition to the 
lymphocytes. T cell proliferation was measured after 6 d of co-culture. Data 
are means and SD of [3H]thymidine incorporation measured on triplicate 
wells and are representative of fi  ve independent experiments.1398  DENDRITIC CELL IMMUNOSUPPRESSION BY MYCOLACTONE | Coutanceau et al.
Mycolactone-treated DCs fail to produce 
chemoattractant molecules
In addition to the IFN-γ response defect in Mu-infected 
  patients, the ulcers are characterized by an abnormally low 
amount of infl  ammation. We therefore evaluated the eff  ect 
of mycolactone on iDC biology, as tissue DCs play an im-
portant role in the initiation of an infl  ammatory response 
and the attraction of innate eff  ector cells to the site of infection. 
We performed a broad screen of infl  ammatory cytokines 
and chemokines produced by DCs after exposure to Toll-
like receptor (TLR) ligands. As shown in Fig. 5 (A and B), 
mycolactone treatment only moderately aff  ected the capac-
ity of mouse or human DCs to produce IL-12 upon stimu-
lation with LPS or poly I:C, TLR-4, and TLR-3 ligands, 
respectively. Similarly, little eff  ect was seen on TNF-α and 
IL-6 production in LPS- or poly I:C–stimulated human DCs 
(Fig. 5, D and E). In mouse DCs stimulated with LPS, 
mRNA expression for IL-6 was not substantially modifi  ed 
(Fig. 5 C). Inhibition of IL-1α and IL-1β mRNA expression was 
observed in LPS-stimulated mouse iDCs, but no comparable 
suppression of IL-1β production could be detected in 
LPS- or poly I:C–stimulated human DCs (unpublished data). 
Therefore, exposure of iDCs to mycolactone during stimula-
tion does not critically modify their expression of infl  amma-
tory cytokines.
In contrast, the production of macrophage infl  ammatory 
protein (MIP) 1α, MIP-1β, regulated on activation, normal 
T cell expressed and secreted (RANTES), IFN-γ–inducible 
protein (IP) 10, and monocyte chemoattractant protein 
(MCP) 1 was markedly reduced by a 24-h exposure of 
  human iDCs to 25 ng/ml mycolactone (Fig. 6). This was 
evident in both LPS- and poly I:C–treated iDCs. However, 
this inhibitory eff  ect was not observed with the neutrophil 
chemoattractant IL-8, the expression level of which was not 
modifi  ed by mycolactone treatment in LPS- or poly I:C–
stimulated human iDCs (Fig. 6). To evaluate whether myco-
lactone endogenously expressed by Mu could mediate similar 
eff  ects, we infected iDCs with WT Mu and compared it with 
a mycolactone-defi  cient mutant (mup045). Interestingly, all 
of the proinfl  ammatory eff  ects of adding the WT Mu were 
Figure 5.  Mycolactone-treated DCs only moderately alter the 
  expression of infl  ammatory cytokines by iDCs. (A) Concentration of 
IL-12 (p40 subunit) in culture supernatants from mouse iDCs stimulated 
with LPS in the presence of 0 or 50 ng/ml mycolactone for 48 h or left 
unstimulated (unstim). (C) IL-1α, IL-1β, and IL-6 mRNA expression is 
shown for mouse iDCs stimulated with LPS for 48 h in the presence of 
increasing doses of mycolactone. (B, D, and E) Production of IL-12 (p70), 
TNF-α, and IL-6 is shown for human peripheral blood–derived iDCs stim-
ulated with LPS or poly I:C in the presence of increasing doses of myco-
lactone for 24 h. Data are means and SD and are representative of two 
independent experiments.JEM VOL. 204, June 11, 2007  1399
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masked by the presence of endogenous mycolactone, whereas 
mup045 was capable of inducing a moderate cytokine and 
chemokine response (unpublished data). In addition, we 
added LPS to the Mu-infected DC cultures and found that 
endogenous mycolactone was indeed capable of inhibiting 
the production of the β-chemokines MIP-1α, MIP-1β, and 
RANTES, as well as MCP-1 and IP-10 (Fig. 7 and not 
depicted). As a control, we added back exogenous mycolac-
tone to the mup045-infected DC cultures. Based on these 
studies, we conclude that the immunosuppressive eff  ects of 
mycolactone account for the abnormal infl  ammatory response 
in BUs.
D  I  S  C  U  S  S  I  O  N 
Until recently, it was assumed that Mu was the only Myco-
bacterium species producing mycolactone. In fact, other 
mycolactone-producing mycobacteria have been isolated from 
fi  sh and frogs presenting ulcerative diseases (14–17). All these 
species contain versions of the Mu virulence plasmid, pro-
duce mycolactones, and show genetic relatedness to Mu and 
M. marinum, a Mycobacterium species causing localized skin 
granulomas in humans and an acute lethal pathology in fi  sh 
(18). On the basis of a genetic analysis, Yip et al. (18) sug-
gested that mycolactone-producing mycobacteria may have 
evolved from a common M. marinum progenitor to form two 
Figure 6.  Mycolactone considerably affects the expression of 
infl  ammatory chemokines by iDCs. The expression of MIP-1α, MIP-1β, 
RANTES, IP-10, MCP-1, and IL-8 chemokines is shown for human 
monocyte-derived iDCs, or TNF-α/PGE2–matured mDCs, after stimulation 
with LPS or poly I:C in the presence of increasing doses of mycolactone 
for 24 h. Data are means and SD and are representative of two indepen-
dent experiments.
Table I.  Inhibition of CD83, CD25, CD80, and CD40 expression in human peripheral blood–derived DCs after stimulation with 
TNF-α/PGE2 in the presence of mycolactone
iDC + TNF-𝗂/PGE2
Treatment duration 24 h 48 h
Mycolactone dose (ng/ml) 20 50 20 50
CD83 43* 77* 53* 67*
CD25 28 34* 33 59*
CD80 1 31 5 24
CD40 4 5 19 37
MFIs of mycolactone-treated DCs were compared with the MFI of control DCs using the Wilcoxon nonparametric test. Mean inhibition percentages calculated on 
n independent experiments (n = 3–6) are shown. *, P < 0.07.1400  DENDRITIC CELL IMMUNOSUPPRESSION BY MYCOLACTONE | Coutanceau et al.
ecotypes causing disease in either ectotherms or endotherms, 
such as humans. The expression of mycolactone-like com-
pounds nevertheless remains restricted to these particular 
species, and no such complex polyketides have thus far been 
isolated from other pathogenic mycobacteria.
Polyketides are a diverse class of secondary metabolites 
produced by polyketide synthases (PKSs). Mycobacteria ex-
press a remarkable arrays of PKSs, which generate multiple 
cell wall–associated lipids (19). At the interface with the host 
immune system, some of these envelope components have 
been shown to be important virulence factors and immune 
modulators. For example, in M. tuberculosis, glycosylation of 
the PKS products phenol phtiodiolones leads to the genera-
tion of phenolic glycolipids, which are potent inhibitors of 
proinfl  ammatory cytokine release by monocyte-derived mac-
rophages (20). With respect to mycolactone, the genetic basis 
of its biosynthesis has been recently elucidated with the isola-
tion of a 174-kb plasmid encoding three modular PKSs (21). 
Interestingly, mycolactone PKSs present highly unusual features 
in terms of size and structure, and mycolactone is the fi  rst 
example of a complex polyketide isolated from pathogenic 
mycobacteria. In fact, the macrocyclic polyketide structure of 
mycolactone shares similarities with that of complex polyketides 
typically produced by fi  lamentous soil actinomycetes such as 
Streptomyces. Strikingly, analysis of the chromosomal sequence 
reveals that numerous PKS genes are inactivated in Mu, sug-
gesting that energy and PKS-specifi  c substrates are preferen-
tially allocated to mycolactone biosynthesis in this species (22). 
In the present study, we demonstrate that this original 
polyketide has the unique capacity to modulate DC functions 
in a selective manner.
The ulcerative properties of Mu have been attributed to 
the cytopathic action of mycolactone, which is able to cause 
growth arrest in cultured fi  broblasts, as well as cell death via 
apoptosis in fi  broblast and macrophage cell models after 3–5 d 
of exposure (23). Cell susceptibility to mycolactone activity 
nevertheless varies with the cell type. For example, Mu lipid 
extracts showed no cytostatic activity on Jurkat T cells, 
whereas they markedly suppressed the cell-cycle progression 
and viability of a mouse pre–B cell line (24). In the present 
study, we found that the susceptibility of DCs to mycolac-
tone cytotoxicity was higher during the immature state. Col-
lectively, these observations suggest that the molecular target 
of mycolactone is ubiquitous in eukaryotic cells but may be 
diff  erentially expressed, depending on the cell type or the cell 
activation state.
Although the mechanism by which mycolactone acts as a 
cytotoxic agent is intriguing, we have focused on the immuno-
suppressive eff  ects of nontoxic doses. We found that myco-
lactone strongly aff  ects the maturation of both mouse and 
human DCs. In particular, we show a failure to up-regulate 
the phenotypic markers of the mature DCs CD83 and CD25, 
and to a lower extent CD80 and CD40. This maturation 
defect was not reversed by removal of mycolactone from cell-
culture medium, suggesting that mycolactone durably aff  ects 
DC maturation. In addition, we demonstrate that mycolac-
tone-treated DCs show a reduced allostimulatory capacity 
and that they are inhibited in their ability to cross-present an-
tigens to T cells (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20070234/DC1). That said, other fea-
tures of maturing DCs remained intact. In particular, phago-
cytic activity of DCs, as measured by the quantity of intracellular 
fl  uorescent beads after 4 h, was not reduced by coincubation 
of the cells with 10–100 ng/ml mycolactone (unpublished data). 
The fact that mycolactone limits the migratory properties of 
DCs, as well as their ability to mature and activate antigen-
specifi  c T cells in vivo (Fig. S3), thus further suggests that 
mycolactone suppresses the capacity of DCs to prime cellular 
immune responses. These fi  ndings may help explain the 
global defect in IFN-γ production by T cells in BU patients 
and the fact that once BU lesions are excised, there is a resto-
ration of Th1 cellular responses (12).
We also explored the eff  ect of mycolactone on the ability 
of DCs to secrete proinfl  ammatory molecules. Surprisingly, 
we observed a selective eff  ect on inducible chemokines. 
In particular, mycolactone blocked the production of the 
monocyte and lymphocyte chemoattractants MIP-1α, MIP-
1β, IP-10, RANTES, and MCP-1. MIP-1α, MIP-1β, and 
Figure 7.  Endogenous production of mycolactone blocks the 
  expression of infl  ammatory chemokines by Mu-infected iDCs. 
The   expression of MIP-1α, MIP-1β, and RANTES is shown for human 
  monocyte-derived iDCs after infection with WT Mu or a mycolactone-
defi  cient mutant (mup045), using an multiplicity of infection of 1:1 or 
5:1 acid-fast bacilli/cell, in the presence of 10 μg/ml LPS. Controls include 
medium only, iDCs stimulated with LPS in the presence of 25 ng/ml 
mycolactone, and iDCs infected with mup045 in the presence of 25 ng/ml 
mycolactone. Data are means and SD and are representative of four 
 independent  experiments.JEM VOL. 204, June 11, 2007  1401
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RANTES are ligands for CC chemokine receptor 5, which 
is specifi  cally expressed by iDCs and Th1 T cells (25, 26). 
Defective production of these infl  ammatory chemokines is 
therefore likely to interfere with both the innate and adap-
tive immune responses to Mu infection. Specifi  cally, decreased 
β-chemokine production by mycolactone-exposed DCs may 
limit the recruitment and activation of iDC precursors to the 
infl  ammation site. In addition, defective production of these 
CC chemokine receptor 5 ligands, as well as the CXC che-
mokine receptor 3 ligand IP-10, is likely to interfere with the 
homing capacity of IFN-γ–secreting T cells to infected tissues. 
This hypothesis is strongly supported by the observation that, 
in contrast to DCs infected with mup045, DCs infected with 
the WT strain failed to produce the chemokines MIP-1α, 
MIP-1β, and RANTES. In accordance with the histopatho-
logical features of BUs, bacterial production of myco  lactone 
may therefore be responsible for suppressing the innate immune 
responses of iDCs, thus preventing the traffi   cking of infl  am-
matory cells to the ulcerative lesion.
The exogenous addition of mycolactone to mup045-infected 
DCs resulted in a strong reduction of their β-chemokine 
response to infection, further demonstrating the critical im-
portance of the toxin in this process. Interestingly, the inhibi-
tion of β-chemokine production by exogenous mycolactone 
in mup045-infected DCs was incomplete, particularly in the 
case of MIP-1β, suggesting that mycolactone may regulate 
the expression of other immunosuppressive agents.
Suppression of these infl  ammatory chemokines was nearly 
complete with minimal doses of mycolactone, whereas the 
expression of the infl  ammatory cytokines TNF-α, IL-12, and 
IL-6 was only marginally modifi  ed. Accordingly, IL-12, IL-1β, 
and TNF-α mRNA were detected at considerable levels in 
lesions from BU patients and were not substantially modu-
lated between the nodular and ulcerative stages of the disease (6), 
suggesting that mycolactone has little impact on the level of 
expression of these cytokines in vivo. Th 1 cellular responses, 
as measured by IFN-γ production, are vigorous during the 
nodular stage of BU and become defective at later stages of 
the disease. From our results, we can propose that, in contrast 
to infl  ammatory cytokines, defective infl  ammatory chemo-
kines may constitute a hallmark of early Mu infection, as well 
as a sensitive indicator of BU progression from the nodular to 
the ulcerative stage.
Given the structural similarity between mycolactone and 
the immunosuppressive drugs FK506 and rapamycin (Fig. S1), 
it is interesting to examine their respective activities. FK506 
and rapamycin are structural analogues binding the same 
intracellular receptor, FKBP12, even though the resulting 
complex targets a different molecule. Although FK506 
and rapamycin are used clinically to suppress activated T cells, 
recent data suggest that they also aff  ect DC diff  erentiation 
and function (27, 28). Interestingly, FK506 has been shown 
to modulate the production of β-chemokines (29, 30). How-
ever, FK506 blocks the production of infl  ammatory cytokines 
such as IL-12 and TNF-α (27), as well as IL-8 (31, 32), all 
molecules that are not altered in mycolactone-treated DCs. 
Our results therefore suggest that mycolactone binds a dif-
ferent molecular target than FK506 or rapamycin. Further 
work will be required to map the precise mechanism under-
lying mycolactone immunosuppressive activity. In con-
clusion, we demonstrate in this study that mycolactone 
inter  feres with DC biology in a unique manner, which helps 
account for the pathologic features of BU. Moreover, we 
show that mycolactone inhibits DC maturation with a se-
lective eff  ect on the chemotactic signals critical for the initi-
ation of an infl  ammatory response. This specifi  city of action 
defi  nes a novel class of potentially useful immunosuppres-
sive agents.
MATERIALS AND METHODS
Bacterial strains. Mu 1615 (Trudeau Mycobacterial Culture Collection 
strain; American Type Culture Collection) was originally isolated in Malaysia 
from human skin biopsies. The mup045 mutant (MU1615::Tn118) possesses 
a transposon insertion inside the mup045 gene, which results in its inability to 
produce mycolactone (3, 21). The Mu 1615 and mup045 mutant strains were 
provided by P.L. Small (University of Tennessee, Knoxville, TN). The bac-
teria were grown on agar plates (7H9; DIFCO) supplemented with 10% oleic 
acid–albumin–dextrose (Becton Dickinson) at 31°C. For infection studies, 
bacteria from exponentially growing cultures were harvested and resuspended 
in a DC culture medium before homogenization by fi  ltration through a sy-
ringe needle and enumeration by the Ziehl-Neelsen procedure. Bacteria were 
added to DC cultures at a multiplicity of infection of 1:1 or 5:1, and plates 
were centrifuged for 2 min at 700 rpm before incubation at 37°C.
Animals. 6-wk-old C57BL/6JIco and OT2 female mice were purchased 
from Charles Rivers Laboratories. Animals were maintained under specifi  c 
pathogen-free conditions and used at 8–12 wk of age. All animal work was 
approved by institutional animal experimentation committees.
Mycolactone preparation. Mycolactone purifi  cation was performed as 
previously described (2). The purity of the preparation was controlled by 
mass spectrometry analysis, as previously described (33).
Generation of DCs from mouse bone marrow. Bone marrow–derived 
DCs were essentially generated by the procedure described by Inaba et al. 
(34). In brief, total bone marrow was recovered from the femurs of C57/BL6 
mice, and cell suspensions were stained with a cocktail of M5/114 (anti–MHC 
class II), RA3-6B2 (anti-B220), HO2.2 (anti-CD8), GK1.5 (anti-CD4), and 
RB6-8C5 (anti–Ly-6G) antibodies, followed by magnetic bead negative 
selection. The remaining cells were cultured in RPMI 1640 supplemented 
with 10% FCS, 50 μM 2-ME, 2.5 ng/ml recombinant mouse GM-CSF and 
10 ng/ml recombinant mouse IL-4.
Generation of DCs from human peripheral blood. PBMCs were 
isolated from whole blood by sedimentation over a Ficoll-Hypaque gradient 
(GE Healthcare). T cell–enriched and T cell–depleted fractions were pre-
pared by adherence to plastic in 1% single donor plasma. iDCs were pre-
pared from the T cell–depleted fraction by culturing cells in the presence of 
1,000 U/ml GM-CSF (Berlex) and 500–1,000 U/ml IL-4 (R&D Systems) 
for 6 d. Cultured cells consisted of >75% CD14– CD83– HLA-DR+ DCs, 
with contaminating cells being B cells and dying myeloid cells. To generate 
mDCs, cultures were stimulated on day 6 with 50 ng/ml TNF-α (Qbiogene) 
and 10 mM PGE2 (Sigma-Aldrich) for 36–48 h, as previously described (23). At 
that time, cells were >85% CD14– CD83+ HLA-DRhi DCs.
DC cytokine production analysis. The production of IL-12 by mouse 
DCs was measured in culture supernatants after a 48-h stimulation with 
10 μg/ml LPS (Sigma-Aldrich) in the presence of mycolactone, using an ELISA 
assay based on the detection of p40 subunit (Biolegend). Expression of cytokine 1402  DENDRITIC CELL IMMUNOSUPPRESSION BY MYCOLACTONE | Coutanceau et al.
mRNA by mycolactone-exposed mouse DCs was also measured after a 
48-h stimulation with 10 μg/ml LPS, using the multiprobe RNase protec-
tion assay (BD Biosciences). In brief, a 32P-labeled mcK-2b template was 
prepared. Total mRNA, isolated from DCs using RNAzol (Cinna/TEL-
TEST), was then hybridized with the probes and digested with RNase. Pro-
tected probes were analyzed by migration on polyacrylamide gel (Bio-Rad 
Laboratories), according to the manufacturer’s protocols. Templates for the 
housekeeping genes L32 and GAPDH were used to normalize the total 
RNA content of the samples.
Cytokine and chemokine release by monocyte-derived DCs was mea-
sured by Luminex (12-plex kit; Biosource International). 30,000–45,000 
iDCs (TNF-α/PGE2–matured DCs) were stimulated with 10 μg/ml LPS or 
poly I:C (Sigma-Aldrich) in 200 μl RPMI 1640 with 1% human serum for 
20 h, in the presence of the doses of mycolactone indicated in the fi  gures. 
Alternatively, 100,000 iDCs were infected with Mu (WT or mup045) and 
incubated for 20 h in the presence of 10 μg/ml LPS. 50 μl of supernatants 
or standard were incubated with antibody-linked beads for 2 h, washed 
twice, and incubated for 1 h with biotinylated secondary antibodies. A fi  nal 
incubation of 30 min with streptavidin-PE was performed before data acqui-
sition (100 events minimum per bead) on a 100 IS apparatus (Luminex). 
Values above or below the standard curves were replaced by the lowest or 
highest concentrations measured.
Allogeneic mixed leukocyte reaction. 2 × 105 purifi  ed T cells per well 
were plated with mDCs exposed to the doses of mycolactone indicated in the 
fi  gures in RPMI 1640 with 5% pooled human serum (Labquip). Co-cultures 
were incubated for 4–5 d at 37°C and pulsed with 1 μCi (0.037 MBq) 
[3H]thymidine during the last 16 h of culture. [3H]thymidine incorporation 
was measured by means of a liquid scintillation counter (Micro96; Skatron).
Skin explant cultures and preparation of ADLN cell suspensions. 
C57BL/6 mice (n = 5) were injected intradermally in the ear with 50 ng 
TNF-α (R&D Systems), with or without 50 μg mycolactone. 4 h later, ani-
mals were killed, and ears were surgically removed. Dorsal and ventral halves 
were split and layered on RPMI 1640 with 10% FCS, 100 mM Hepes, and 
100 μg/ml penicillin. After 24 h at 37°C, ear skin explant migrating cells 
were pooled and fi  ltered through a 70-μm nylon mesh before antibody 
staining. ADLN cells were dissociated from the matrix by a 25-min incuba-
tion at 37°C with 1 mg/ml collagenase D and 40 μg/ml DNase I (Roche 
Diagnostics) in RPMI 1640. Cells were collected and washed in PBS before 
FACS analysis.
Online supplemental material. Fig. S1 shows the structures of mycolac-
tone, cyclosporin A, rapamycin, and FK506. Fig. S2 depicts in vitro cross-
presentation studies. Fig. S3 shows that mycolactone inhibits the capacity of 
DCs to prime lymphocytes in vivo. The percentage of proliferating CFSE+ 
cells was calculated as previously described (35). Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20070234/DC1.
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